LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models-Reference-Cited by-同舟云学术

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Published:2012-12-29 Issue:4 Volume:31 Page:833-844
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Yan S. Betty,Peek Victoria L.,Ajamie Rose,Buchanan Sean G.,Graff Jeremy R.,Heidler Steven A.,Hui Yu-Hua,Huss Karen L.,Konicek Bruce W.,Manro Jason R.,Shih Chuan,Stewart Julie A.,Stewart Trent R.,Stout Stephanie L.,Uhlik Mark T.,Um Suzane L.,Wang Yong,Wu Wenjuan,Yan Lei,Yang Wei J.,Zhong Boyu,Walgren Richard A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-012-9912-9.pdf

Reference39 articles.

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–25

2. Comoglio PM, Giordano A, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Disc 7:504–16

3. Turke AB, Zejnullahum K, Wu YL, Song Y, Dias-Santagata D, Lifshits E et al (2010) Preexistence and clonal selection of Met amplification in EGFR mutant NSCLC. Cancer Cell 17:77–88

4. Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K et al (2011) Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thoracic Oncol 7:272–80

5. Bean J, Brennan C, Shih JY, Riely GJ, Viale A, Wang L et al (2007) Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Nat’l Acad Sci USA 104:20932–7

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment;Journal of Medicinal Chemistry;2024-06-24

2. Recent discovery and development of AXL inhibitors as antitumor agents;European Journal of Medicinal Chemistry;2024-06

3. Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer;Cancer Letters;2024-04

4. Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy;European Journal of Medicinal Chemistry;2024-02

5. Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy;European Journal of Medicinal Chemistry;2024-02